Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients - Wikidata - awgldk - TriplyDB

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

http://www.wikidata.org/entity/Q34463433

about

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness Phosphate binders in chronic kidney disease: a systematic review of recent data.Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.Advances in pharmacotherapy for hyperphosphatemia in renal disease.A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Emerging drugs for the treatment of kidney disease-induced anemia.Treating hyperphosphatemia - current and advancing drugs.Phosphate binders in patients with chronic kidney disease.Treatment of renal anemia: Erythropoiesis stimulating agents and beyond.Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.A regenerable potassium and phosphate sorbent system to enhance dialysis efficacy and device portability: a study in awake goats.Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.

P2860

Q26764806-DF875E2B-D470-48FE-9FFD-2EE52E20BBC2 Q26786000-92EFB3E2-6166-4A3A-BB9F-BCE98D04EB14 Q31039292-3BFD02F0-EBF6-4D93-A5F9-990B59AC5366 Q33840398-7DA03B04-5FE5-4DFC-B04D-D12BC07A4638 Q36225208-73B593E3-886A-45C0-9DE9-5FBDCF8150E1 Q36322947-2863093C-0CCE-467F-8341-349C82C799D3 Q37069943-483BCABF-A3B1-41A7-BB8C-576F1C13F66C Q37696553-47791601-DCB0-4948-8C98-6A3409CEA6AF Q38587575-31DEBC0A-EC8D-4DC8-A924-C9E4541F416B Q38741675-1DDE00FE-90F1-4F15-AF8B-818F4A01D6F5 Q38819231-BEB113C6-65EF-478A-9AAF-4DD380AA28D3 Q38828902-DAF64650-ED78-4D57-BDD2-5CD5533D2CA0 Q38930912-A274F5B4-5A0D-4B46-8C3F-A6F242BD4051 Q38958363-7E6E8716-7507-4B73-A5D0-E1C9E924FE4E Q39155279-BC63B978-D3A6-405C-ACD8-77E9A85D27BE Q41387413-AE70BE10-B86D-41B8-89D4-6CA13B4D5454 Q45853530-462A203B-F7E7-40EC-87D0-B464D6EC80DC Q46034498-C832846E-54E8-451B-BF81-AAA3AB7DB29F Q46547077-62C23560-6353-4AA3-81F2-49E968FA0B57 Q49279657-D6726B82-13AF-4C25-A46C-2E53673575AF Q51318751-68517486-0D8E-4348-951C-F9517441F332 Q51743408-803F51D0-0DA4-42C9-98F1-44BF9F821195 Q53775627-5F29FB92-BE64-470E-912B-CC64A160E0E2 Q55347421-09C578F9-DC7A-4B26-9F88-C512515BAF82

P2860

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

http://www.wikidata.org/entity/Q34463433

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@ast

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@en

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@nl

type

label

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@ast

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@en

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@nl

prefLabel

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@ast

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@en

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@nl

P1433

Q34463433-1F4B6A89-0D10-4BC3-9331-710D2D813F08

P1476

Q34463433-AE0BC7B0-543F-4037-B150-E7C9A8354FAA

P2093

Q34463433-19909824-8FC8-4E5E-991A-01DF5CF0E37A

Q34463433-3DD41B89-C5BF-4EC2-AC33-CA845A7260ED

Q34463433-45D2621A-897F-49E6-8FCA-4920AB23D61E

Q34463433-52533912-C401-475D-9FED-F9C29F39E440

Q34463433-687615D0-DBD0-43CA-B265-23AE39CA850C

Q34463433-7DC73F8E-94B3-4F51-A813-0D7EBA59BAA9

Q34463433-85610247-35C6-409A-A298-3E099DCD7A8B

Q34463433-9C8591B2-697D-4321-A6A9-64925E15B7F0

Q34463433-ABB092D3-2531-4292-9DFB-AA770B8E13A2

Q34463433-CB302D10-EE1E-4BB3-BADD-596E4163691F

P2860

Q34463433-0426FCF7-45D8-40C2-B936-9CD32036561D

Q34463433-36527AB7-2135-42FE-B9DC-7E093AED3F6A

Q34463433-42F5A20F-3270-4551-BCF5-4AA2E1253654

Q34463433-7A9FB7FE-39BD-4EED-A699-D372AC5A01EF

Q34463433-805B33CD-06CA-47D7-8EF4-047792B075BA

Q34463433-87251C3F-CE08-4500-9A7F-5DD3F886843A

Q34463433-9F6A0DCD-402F-4C8B-8CF5-1414B4EBF891

Q34463433-9FF5A007-BFA7-443D-B758-D9C8CC5B9E5A

Q34463433-A1056DF5-0A22-492E-91B5-CC3F482445F7

Q34463433-A83E0E2B-1466-4374-B4B9-68DC3A64F0BE

P304

Q34463433-BDBD2A04-2F86-418C-A4FC-F99C77078169

P31

Q34463433-4D901AE4-869D-4B7C-81E0-38B2F718E8F6

P356

Q34463433-3D1DC2F6-C252-491D-8546-79A94FA6315A

P407

Q34463433-DE7468AA-0B86-4F9B-9B82-690F9976D493

P433

Q34463433-CFA43D1C-9263-4884-9329-E2B6217CC8A9

P478

Q34463433-6B7A5F6C-135F-448C-974E-E8A106B66025

P577

Q34463433-AA861493-B949-4560-AD6D-A396F57A9DC3

P5875

Q34463433-ADA9892A-136C-4037-A1DD-1C0B31BC985C

P698

Q34463433-897D0F73-1B7C-4447-96DA-D109F9707023

P921

Q34463433-0A3FCF38-5EB1-489F-BC75-00365B0BE9AD

Q34463433-D8E5847A-A2D5-430A-A653-4B7F076BC8C4

P932

Q34463433-D8F87CD2-9B91-4E94-8C91-06BA4C584208

P356

P1433

Nephrology Dialysis Transplantation

P1476

Long-term effects of the iron- ...... ydroxide, in dialysis patients

@en

P2093

Adrian C Covic

http://www.w3.org/2001/XMLSchema#string

Anjay Rastogi

http://www.w3.org/2001/XMLSchema#string

Bruce Spinowitz

http://www.w3.org/2001/XMLSchema#string

Edward M F Chong

http://www.w3.org/2001/XMLSchema#string

Johannes F E Mann

http://www.w3.org/2001/XMLSchema#string

Jürgen Floege

http://www.w3.org/2001/XMLSchema#string

Laura J Lisk

http://www.w3.org/2001/XMLSchema#string

Markus Ketteler

http://www.w3.org/2001/XMLSchema#string

Stuart M Sprague

http://www.w3.org/2001/XMLSchema#string

Sucroferric Oxyhydroxide Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review.

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis.

Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis).

Phosphorus binders and survival on hemodialysis.

The roles of the skeleton and phosphorus in the CKD mineral bone disorder

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.

P304

1037-1046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFV006

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272514081

http://www.w3.org/2001/XMLSchema#string

P698

25691681

http://www.w3.org/2001/XMLSchema#string

P921

P932

4438742

http://www.w3.org/2001/XMLSchema#string